Skip to content
Menu

Chemomab Therapeutics Ltd. CMMB

Full chart Compare
Set alert

Price alert · CMMB

All alert types
1.14 USD -0.41 (-26.45%)

Regular-session close

1.15 +0.01 +0.88%

After hours · Nov 19, 4:00 PM ET

1.10 Day range 1.58
0.92 52-week range 2.99
YTD
-30.91%
1 year
-57.78%

 

No chart data for this range yet.
Market cap
9.18M
EPS (ttm)
-1.04
Shares out
18.86M
Forward P/E
-41.25
YTD return
-30.91%
1-year return
-57.78%
50-day average
1.57
200-day average
1.23
Volume
91.28K
Avg volume
102.94K
Open
1.54
Previous close
1.55
Day's range
1.10 – 1.58
52-week range
0.92 – 2.99
Beta
0.30
Price target
8.00 (+601.8%)

Key statistics

Enterprise value
447.13M
Price / book
1.38
Free cash flow
-11.36M
Total cash
12.73M
Total debt
360.00K
Return on equity
-93.80%
Short % of float
0.87%

Fundamental scorecard

6 of 25 checks passed on CMMB’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 5 of 5
  • Dividend No data

Statements to Jun 30, 2026.

Financials — quick view

All financials
CMMB Revenue — quarterly 0
CMMB Net income — quarterly -2.17M
CMMB EPS — quarterly -0.24

Earnings

CMMB recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 14, 2024Sep 1, 2024-0.20-0.200.000.00%
Aug 21, 2024Jun 1, 2024-0.20-0.26-0.06-30.00%
Aug 21, 2024Jun 1, 2024-0.20———
May 9, 2024Mar 1, 2024-0.20-0.28-0.08-40.00%
May 9, 2024Mar 1, 2024-0.20———
Mar 7, 2024Dec 1, 2023-0.40-0.26+0.14+35.00%

Upgrades / downgrades

CMMB analyst upgrades and downgrades
DateFirmActionFromTo
Nov 15, 2024OppenheimerreitOutperformOutperform
May 13, 2024Maxim Groupinit—Buy
May 6, 2024OppenheimerupPerformOutperform
Mar 8, 2024OppenheimermainPerformPerform
Oct 6, 2023Roth MKMinit—Buy
Jun 7, 2023OppenheimerdownOutperformPerform

About Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Sector
Healthcare
Industry
Biotechnology
Country
Israel
Website
chemomab.com

News

Your note

Sign in to keep a note on CMMB — it syncs with the Stock Master app.

Insider holders

CMMB insider holders
InsiderRelationLatest transactionDateShares held
MOR GEORGE ADIOfficer and DirectorSaleJan 2, 20230
ORBIMED ISRAEL GP LTD.Beneficial Owner of more than 10% of a Class of SecuritySaleJan 2, 20230

Institution ownership

CMMB institution ownership
Holder% heldSharesValueReported
Orbimed Advisors LLC.9.23%1,741,2732.87MSep 29, 2024
Sphera Funds Management Ltd.6.44%1,214,5752.00MSep 29, 2024
Yelin Lapidot Holdings Management Ltd.4.29%809,7171.34MSep 29, 2024
Morgan Stanley2.13%402,272663.75KSep 29, 2024
Ikarian Capital, LLC1.13%213,392352.10KSep 29, 2024
Two Sigma Securities, LLC0.21%39,93965.90KSep 29, 2024

Fund ownership

CMMB fund ownership
Holder% heldSharesValueReported
Blackstone Alternative Multi-Strategy Fund0.00%200329Jun 29, 2024